Platelet-derived growth factor-B (PDGF-B) promotes tumor metastasis by inducing tumor cell growth, invasion, and angiogenesis in several cancers. However, the roles of PDGF-B in gastric carcinoma are largely unknown. We established two gastric carcinoma cell lines, SGC7901 and BGC823, to stably overexpress PDGF-B by lentiviral vectors, and determined their growth, invasion and angiogenesis. Overexpression of PDGF-B significantly enhanced the cell proliferation, invasion and angiogenesis of both SGC7901 and BGC823 cells, accompanied with increased activation of AKT, which is a downstream target of PDGF signaling pathway. Consequently, an AKT kinase inhibitor abolished the PDGF-B overexpression-mediated up-regulation of growth, invasion and angiogenesis. These results indicate that PDGF-B signaling may promote the metastasis of gastric carcinoma through AKT signaling. Targeting the PDGF-B pathway may be an alternative strategy for the development of therapies for gastric cancers.
described by Lois et al. [17] and Xia et al. [18] . Briefly, primers were designed according to the PDGF-B sequence (Genbank Accession Number NM_002608.2). The primer sequences are: PDGF-B-F, 5'-ATGAATCGCTGCTGGGCGCTC-3'; PDGF-B-R, 5'-CTAGGCTCCAAGGGTCTCCTTC-3' . Target gene was obtained by Polymerase Chain Reaction (PCR) and was inserted into the pUC57 vector. Then, both pLenO-DCE and pUC57-PDGF-B were enzyme digested by EcoR I and Not I respectively. After ligation, the pLenO-DCE-PDGF-B vector was constructed. After sequencing, pLenO-DCE-PDGF-B vector was transfected into 293T cells and lentiviral-delivered PDGF-B vector was prepared.
Cell transfection. Briefly, 1×10 5 SGC7901 and BGC823 cells were seeded in each well of a 6-well plate in 500μl of complete media at 37°C in a 5% CO 2 incubator for 24 h, and then transduced by lentiviral vectors at a multiplicity of infection of 10:1 [19] . Transduction was carried out in the presence of Polybrene (8μg/ml). After washing three times with PBS, 1ml of RPMI1640 was added in each well. Cells were seeded at 37 °C in a 5% CO 2 incubator for 48 h. Fluorescence microscopy was used to observe the transduction. G418 (400 μg/ml) was used for screening. Transduced cells were passaged and seeded for further experiments.
MTT assay. Cells (5 x 10 3 ) were seeded in a 96-well plate (BD Biosciences, USA) and harvested for the MTT assay at indicated times from days 1-6. Cell samples were incubated with 20 μl of MTT (5mg/mL; Sigma, USA) for 6 h. Following the removal of the MTT solution, formazan crystals were dissolved in 150 μl of dimethyl sulfoxide (DMSO, Sigma, USA). The absorption of the solution was measured at 570 nm [20] .
Transwell invasion assay. Invasion chambers coated with Matrigel were purchased from BD Biosciences. Assays were conducted as described by Sarah E et al. [21] . Briefly, cells (1×10 5 ) were added to the top chambers (300μl RPMI1640) of 24-well transwell plates (BD Biosciences; 8 μm pore size). After 24 h, the top (non-migrated) cells were removed, and the bottom (migrated) cells were fixed with 70% methanol andstained with trypan blue to visualize nuclei. The number of migrating cells in five fields was counted under 100× magnification, and the mean for each chamber was determined with ImageJ (version 1.38, National Institutes of Health). Experiments were repeated for a minimum of three times.
Matrigel assay. The bottoms of cell chambers were coated with a 300 microliter (µl) mixture of Matrigel (50mg/L) without anti-serum (ratio:1:2), and was preheated at 37°C for 30 min. HUVECs (5×10 4 ) were added to the top chambers (300 μl RPMI1640) of 24-well transwell plates. 6×100 μl supernatant from PDGF-B overexpressed SGC7901 and BGC823 gastric carcinoma cells and 6×100 μl supernatant from normal SGC7901 and BGC823 gastric carcinoma cells were added in each well with RPMI1640 (ratio:1:2). After 24 h, the number of neovessels (number of nodes×the number of branches/perimage) was calculated under 400× magnification according to Chigurupaliet al [22] .
Western blot analysis. Cells were lysed on ice in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 2 mM sodium fluoride, 2 mM Na 3 VO4 2 , 1 mM EDTA, and 1 mM EGTA). Total protein extracts were analyzed by western blotting, as described previously [23] . Proteins (20 µg) were separated by SDS-PAGE gels (Invitrogen) and transferred to PVDF membranes. The membranes were blotted for 1 h with 5% milk. Membranes were incubated with primary antibodies (1:500 dilution) against AKT-1or p-AKT-S473 (Santa Cruz Biotechnology, Inc. USA) at 4°C for overnight. After incubation with horseradish peroxidase-conjugated secondary antibody (1:1000 dilution) for 3h at 37°C, signals were detected by ECL chemiluminescence for 5 min. The films were analyzed by densitometry with image software.
Statistics analysis. Data were expressed as mean±SE and statistically evaluated by one-way ANOVA followed by a Newman-Keuls test. P<0.05 was considered statistically significant.
Results

PDGF-B overexpression increased the activity of AKT-1 in SGC7901 and BGC823 gastric carcinoma cells.
To check the overexpression of PDGF-B in our stably transfected cells and see if overexpression of PDGF-B leads to increased activation of AKT, we checked the pAKT-S473, a marker for the activity of AKT pathway, in our SGC7901 and BGC823 gastric carcinoma cells, which has been transduced with lentiviral constructs to overexpress PDGF-B. As illustrated in Figure 1 , our stably transduced cells overexpressed PDGF-B, and PDGF-B overexpression significantly increased both the protein levels of AKT-1 and the phosphorylation of AKT at phosphorylation site S-473 (p<0.05) (Fig. 1) , supporting the previous finding that ATK is a downstream signaling target of the PDGF pathway [24, 25] .
Overexpression of PDGF-B increased the cell growth of SGC7901 and BGC823 gastric carcinoma cells. We determined the cell growth of SGC7901, PDGF-B overexpression SGC7901 (SGC7901/PDGF-B), BGC823 and PDGF-B overexpression BGC823 (BGC823/PDGF-B) cells. We also determined the cell growth of SGC7901, PDGF-B overexpression SGC7901 (SGC7901/PDGF-B), BGC823 and PDGF-B overexpression BGC823 (BGC823/PDGF-B) cells after being treated with an AKT inhibitor. Compared with SGC7901 and BGC823 cells, the cell growth of SGC7901/PDGF-B and BGC823/PDGF-B cells increased significantly (p<0.05) (Fig. 2) . In consistence with the activation of AKT by PDGF-B (Fig. 1) , treatment with an AKT inhibitor significantly reduced the cell growth of SGC7901/PDGF-B and BGC823/PDGF-B cells (p<0.05), but treatment with an AKT inhibitor did not reduce the cell growth of SGC7901 and BGC823 (p>0.05). Significant differences were not observed between SGC7901/PDGF-B and BGC823/PDGF-B cells treated with an AKT inhibitor and normal SGC7901 and BGC823 cells (p>0.05) (Fig. 2) . (SGC7901/PDGF-B AKT inhibitor) and AKT inhibitor added PDGF-B overexpression BGC823 (BGC823/PDGF-B AKT inhibitor) cells. Then endothelial cell tube formation was assessed. As shown in Figure 4 , numerous endothelial tubes were formed after treatment with the different supernatants. However, tube formation was significantly increased when HUVECs were treated with SGC7901/PDGF-B supernatant (219±11) compared to SGC7901 supernatant (83±3) (p<0.05). Moreover, tube formation was significantly increased when HUVECs were treated with BGC823/PDGF-B supernatant (229±13) when compared with BGC823 supernatant (94±5) (p<0.05). In contrast, tube formation was significantly reduced when HUVECs were treated with SGC7901/PDGF-B AKT inhibitor supernatant (97±6), compared to that treated with SGC7901/PDGF-B supernatant (p<0.05). Similarly, tube formation was significantly decreased when treated with BGC823/PDGF-B AKT inhibitor supernatant (102±6), as compared to HUVECs treated with BGC823/PDGF-B supernatant (p<0.05). These results demonstrated that PDGF-B overexpression increased the angiogenesis of SGC7901 and BGC823 cells, and was abolished when these cells were treated with an AKT inhibitor.
Discussion
PDGF-B is highly expressed in many types of human cancers, including colorectal cancer [26] , gastric cancer [16] , liver cancer [27] and thyroid cancer [28] , suggesting that PDGF-B may play an important role in the progression, development, invasion and angiogenesis of cancers. Recently, Kodamaet al. [12] and Suzukiet al. [16] reported that PDGF-B was overexpressed in gastric carcinoma, but the functions of PDGF-B in gastric carcinoma remained to be determined. To investigate the role of the PDGF-B signaling pathway in gastric carcinoma, we examined the alteration of cell growth, invasion and angiogenesis of gastric carcinoma cells after overexpressing PDGF-B.
We up-regulated the expression of PDGF-B by transfection of SGC7901 and BGC823 gastric carcinoma cells with PDGF-B constructs. Our data demonstrated that PDGF-B overexpression resulted in a promotion of cell growth, invasion and angiogenesis of SGC7901 and BGC823 cells. These findings indicate that PDGF-B plays an important role in tumor progression. Since tumor progression inhibition is the prerequisite for efficient tumor therapy [29, 30] , PDGF-B might be a promising target for tumor therapy. Our data indicate that activation of the PI3K-AKT pathway may be one of the underlying mechanisms by which PDGF-B signaling up-regulates the cell growth, invasion and angiogenesis of gastric carcinoma cells.
PI3K-AKT/PKB signaling, a prominent cancer cell growthpromoting pathway [31] , can be activated by many types of growth factors to promote cell growth, migration and invasion of tumor cells [32, 33, 34] . Although many studies have demonstrated the role of PDGF-B in gastric carcinoma progression [12, 16] ,we sought to investigate whether the effects of PDGF-B up-regulation on gastric carcinoma was mediated through activation of AKT/PKB signaling. We found PDGF-B overexpression increased the activity of AKT in SGC7901 and BGC823 gastric carcinoma cells, and treatment with an AKT inhibitor reduced gastric carcinoma cell growth, invasion and angiogenesis. Thus, we propose that PDGF-B up-regulation increases gastric carcinoma progression, at least partially, through the activation of AKT/PKB signaling. Further studies are needed to determine themolecular mechanism(s) by which PDGF-B regulates AKT/PKB signaling.
In summary, we determined that PDGF-B promoted the cell growth, invasion, and angiogenesis of gastric carcinoma cells through AKT/PKB signaling, suggesting that PDGF-B plays an important role in the tumor progression and development of gastric carcinoma. Targeting the PDGF-B signaling pathway may be a reasonable approach in treating gastric carcinoma.
